Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a multisystemic disease, i.e., influencing various organ systems beyond the liver and, thus, contributing to comorbidities. Characterized by excessive fat accumulation in the hepatocytes, MASLD is frequently linked to metabolic synd...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/61/1/38 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588013569310720 |
|---|---|
| author | Myrsini Orfanidou Stergios A. Polyzos |
| author_facet | Myrsini Orfanidou Stergios A. Polyzos |
| author_sort | Myrsini Orfanidou |
| collection | DOAJ |
| description | Metabolic dysfunction-associated steatotic liver disease (MASLD) is a multisystemic disease, i.e., influencing various organ systems beyond the liver and, thus, contributing to comorbidities. Characterized by excessive fat accumulation in the hepatocytes, MASLD is frequently linked to metabolic syndrome components, such as obesity, insulin resistance, dyslipidemia, and hypertension. Therefore, exploring the intricate connection between MASLD and other organ systems, including the eyes, seems to be essential. In this context, retinopathy has been investigated for its potential association with MASLD, since both conditions share common pathogenetic pathways. Chronic low-grade inflammation, oxidative stress, insulin resistance, and endothelial dysfunction are only some of those mechanisms contributing to disease progression and, possibly, determining the bidirectional interplay between the liver and retinal pathology. This narrative review aims to summarize data concerning the multisystemicity of MASLD, primarily focusing on its potential association with the eyes and, particularly, retinopathy. Identifying this possible association may emphasize the need for early screening and integrated management approaches that address the liver and eyes as interconnected components within the framework of a systemic disease. Further research is necessary to delineate the precise mechanisms and develop targeted interventions to mitigate the bidirectional impact between the liver and eyes, aiming to reduce the overall burden of disease and improve patient outcomes. |
| format | Article |
| id | doaj-art-b81842e7c49c41289b874d6fd88f3361 |
| institution | Kabale University |
| issn | 1010-660X 1648-9144 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj-art-b81842e7c49c41289b874d6fd88f33612025-01-24T13:40:20ZengMDPI AGMedicina1010-660X1648-91442024-12-016113810.3390/medicina61010038Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver DiseaseMyrsini Orfanidou0Stergios A. Polyzos1First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, GreeceFirst Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, GreeceMetabolic dysfunction-associated steatotic liver disease (MASLD) is a multisystemic disease, i.e., influencing various organ systems beyond the liver and, thus, contributing to comorbidities. Characterized by excessive fat accumulation in the hepatocytes, MASLD is frequently linked to metabolic syndrome components, such as obesity, insulin resistance, dyslipidemia, and hypertension. Therefore, exploring the intricate connection between MASLD and other organ systems, including the eyes, seems to be essential. In this context, retinopathy has been investigated for its potential association with MASLD, since both conditions share common pathogenetic pathways. Chronic low-grade inflammation, oxidative stress, insulin resistance, and endothelial dysfunction are only some of those mechanisms contributing to disease progression and, possibly, determining the bidirectional interplay between the liver and retinal pathology. This narrative review aims to summarize data concerning the multisystemicity of MASLD, primarily focusing on its potential association with the eyes and, particularly, retinopathy. Identifying this possible association may emphasize the need for early screening and integrated management approaches that address the liver and eyes as interconnected components within the framework of a systemic disease. Further research is necessary to delineate the precise mechanisms and develop targeted interventions to mitigate the bidirectional impact between the liver and eyes, aiming to reduce the overall burden of disease and improve patient outcomes.https://www.mdpi.com/1648-9144/61/1/38hepatic fibrosismetabolic dysfunction-associated steatotic liver diseasemetabolic dysfunction-associated steatohepatitisnonalcoholic fatty liver diseasenonalcoholic steatohepatitisocular disease |
| spellingShingle | Myrsini Orfanidou Stergios A. Polyzos Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease Medicina hepatic fibrosis metabolic dysfunction-associated steatotic liver disease metabolic dysfunction-associated steatohepatitis nonalcoholic fatty liver disease nonalcoholic steatohepatitis ocular disease |
| title | Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease |
| title_full | Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease |
| title_fullStr | Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease |
| title_full_unstemmed | Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease |
| title_short | Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease |
| title_sort | retinopathy in metabolic dysfunction associated steatotic liver disease |
| topic | hepatic fibrosis metabolic dysfunction-associated steatotic liver disease metabolic dysfunction-associated steatohepatitis nonalcoholic fatty liver disease nonalcoholic steatohepatitis ocular disease |
| url | https://www.mdpi.com/1648-9144/61/1/38 |
| work_keys_str_mv | AT myrsiniorfanidou retinopathyinmetabolicdysfunctionassociatedsteatoticliverdisease AT stergiosapolyzos retinopathyinmetabolicdysfunctionassociatedsteatoticliverdisease |